TWA
MRTX

TCI Wealth Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

TCI Wealth Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25
Closed -$1.13K – 2674
2022
Q4 		$1.13K Buy
+25
New +$1.62K ﹤0.01% 2095
2022
Q1 		– Sell
-1
Closed – – 2530
2021
Q4 		$0 Buy
+1
New +$155 ﹤0.01% 2582
2021
Q2 		– Sell
-45
Closed -$8K – 2498
2021
Q1 		$8K Buy
+45
New +$8.91K ﹤0.01% 1017

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TCI Wealth Advisors's MRTX Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 25 shares — an estimated $1.13K sold.

TCI Wealth Advisors first reported a position in MRTX in Q1 2021 and held it in 3 quarters. The position peaked at $8K in Q1 2021. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 25 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.13K.
  • TCI Wealth Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $8K in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.